{"id":1045,"date":"2014-10-26T09:39:37","date_gmt":"2014-10-26T13:39:37","guid":{"rendered":"http:\/\/blogs.shu.edu\/cancer\/?p=1045"},"modified":"2021-07-02T08:51:57","modified_gmt":"2021-07-02T12:51:57","slug":"immunotherapy-of-cancer-roche-newlink-1-billion-deal-for-ido-inhibition","status":"publish","type":"post","link":"http:\/\/blogs.shu.edu\/cancer\/2014\/10\/26\/immunotherapy-of-cancer-roche-newlink-1-billion-deal-for-ido-inhibition\/","title":{"rendered":"Immunotherapy of Cancer:  Roche &amp; NewLink $1 Billion Deal for IDO Inhibition"},"content":{"rendered":"<p>Roche (Genentech) entered into a <a href=\"http:\/\/www.firstwordpharma.com\/node\/1241134#axzz3GWDaYJy9\" target=\"_blank\" rel=\"noopener\">$1 billion deal with NewLink Genetics<\/a>, a company with an IDO (indoleamine 2,3-dioxygenase) inhibitor.<!--more--> IDO is secreted by cancer cells and Treg cells \u2013 it causes the oxidation of tryptophan, which cytotoxic T-cells need. Thus, IDO <a href=\"http:\/\/blogs.shu.edu\/cancer\/2014\/08\/06\/ido-inhibition-in-cancer-immunology\/\" target=\"_blank\" rel=\"noopener\">acts like a checkpoint control mechanism that abrogates the immune response<\/a>. Several companies \u2013 Incyte, BMS, and Regen BioPharma \u2013 are developing IDO inhibitors.<\/p>\n<p><a href=\"http:\/\/newlinkgenetics.com\/ido-pathway-inhibitors\" target=\"_blank\" rel=\"noopener\">NewLink\u2019s NLG919<\/a> is in Phase 1 testing. Roche paid $150 MM upfront to NewLink. The companies will collaborate on the development of second generation IDO inhibitors, as well.<\/p>\n<p><a href=\"http:\/\/blogs.shu.edu\/cancer\/files\/2014\/10\/ido_pathway_inhibitors.png\" data-rel=\"lightbox-image-0\" data-rl_title=\"\" data-rl_caption=\"\" title=\"\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-1046 size-full\" src=\"http:\/\/blogs.shu.edu\/cancer\/files\/2014\/10\/ido_pathway_inhibitors.png\" alt=\"ido_pathway_inhibitors\" width=\"557\" height=\"405\" srcset=\"http:\/\/blogs.shu.edu\/cancer\/files\/2014\/10\/ido_pathway_inhibitors.png 557w, http:\/\/blogs.shu.edu\/cancer\/files\/2014\/10\/ido_pathway_inhibitors-300x218.png 300w\" sizes=\"auto, (max-width: 557px) 100vw, 557px\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche (Genentech) entered into a $1 billion deal with NewLink Genetics, a company with an IDO (indoleamine 2,3-dioxygenase) inhibitor.<\/p>\n","protected":false},"author":2252,"featured_media":294,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[28,303,1],"tags":[547,546,548,224],"class_list":["post-1045","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-checkpoint-inhibitors","category-ido","category-uncategorized","tag-checkpoint-inhibitors-2","tag-ido-inhibition","tag-newlink","tag-roche"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/1045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/users\/2252"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/comments?post=1045"}],"version-history":[{"count":4,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/1045\/revisions"}],"predecessor-version":[{"id":4991,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/1045\/revisions\/4991"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/media\/294"}],"wp:attachment":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/media?parent=1045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/categories?post=1045"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/tags?post=1045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}